ProDigest
0806.567.272 · rovalta.com · 21/09/2026
ProDigest
Overview
What does ProDigest do?
ProDigest is a Private limited company incorporated in 2008. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Gent. It employs on average 39,8 ETP workers (FTE).
9052 Gent · FlandreSee on map
Joint committees (2)
- 207
- 20700
Trend over 15 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||||||||||||||||||
| Gross margin | 4,2 M € | -0.4% | 4,2 M € | +20.3% | 3,5 M € | -6.1% | 3,7 M € | -36.5% | 5,9 M € | +99.4% | 3 M € | +25.1% | 2,4 M € | +5.5% | 2,2 M € | +25.2% | 1,8 M € | +11.3% | 1,6 M € | +91.1% | 841,6 k € | +57.3% | 535 k € | +25.8% | 425,4 k € | +19.4% | 356,3 k € | -0.9% | 359,5 k € |
| EBITDA | 582,3 k € | -10.9% | 653,7 k € | +273% | -377,2 k € | -194% | 402,6 k € | -86.7% | 3 M € | +864% | 313,6 k € | -38.6% | 510,6 k € | -53.6% | 1,1 M € | +4.0% | 1,1 M € | +6.8% | 990,4 k € | +140% | 413 k € | +102% | 204,3 k € | -24.0% | 268,7 k € | +13.0% | 237,8 k € | -9.1% | 261,6 k € |
| Operating result | 1,3 k € | -98.6% | 93,4 k € | +111% | -857,4 k € | -1621% | 56,4 k € | -98.0% | 2,8 M € | +9821% | 28,1 k € | -90.1% | 285 k € | -68.5% | 903,4 k € | -1.3% | 915,3 k € | +6.2% | 862,1 k € | +181% | 306,7 k € | +133% | 131,6 k € | -46.6% | 246,6 k € | +12.9% | 218,4 k € | -12.5% | 249,5 k € |
| Net result | 32,7 k € | -70.5% | 111 k € | +113% | -842,7 k € | -8028% | 10,6 k € | -99.5% | 2,2 M € | +23992% | 9 k € | -96.5% | 256,9 k € | -58.4% | 616,8 k € | -4.0% | 642,7 k € | +8.2% | 594,1 k € | +159% | 229,7 k € | +88.6% | 121,8 k € | -32.5% | 180,5 k € | +26.6% | 142,6 k € | -13.7% | 165,3 k € |
| Balance sheet | |||||||||||||||||||||||||||||
| Equity | 5,2 M € | +0.6% | 5,1 M € | +2.2% | 5 M € | -14.4% | 5,9 M € | +0.2% | 5,9 M € | +179% | 2,1 M € | +0.4% | 2,1 M € | +14.1% | 1,8 M € | +50.9% | 1,2 M € | +51.7% | 798,4 k € | +83.8% | 434,3 k € | +27.7% | 340,2 k € | +24.5% | 273,3 k € | +58.2% | 172,8 k € | +72.4% | 100,3 k € |
| Total assets | 7,8 M € | +1.0% | 7,8 M € | -11.2% | 8,7 M € | +4.2% | 8,4 M € | -2.1% | 8,6 M € | +77.0% | 4,8 M € | +0.0% | 4,8 M € | +47.6% | 3,3 M € | +13.1% | 2,9 M € | +0.3% | 2,9 M € | -17.3% | 3,5 M € | +107% | 1,7 M € | +177% | 610,3 k € | +32.6% | 460,3 k € | +42.8% | 322,4 k € |
| Cash | 654,6 k € | +43.4% | 456,5 k € | +10.4% | 413,6 k € | -81.3% | 2,2 M € | -31.4% | 3,2 M € | +238% | 952,4 k € | +47.4% | 646,2 k € | -41.2% | 1,1 M € | +116% | 508,2 k € | -23.5% | 664 k € | -44.7% | 1,2 M € | +186% | 420,3 k € | +177% | 151,7 k € | +57.4% | 96,4 k € | -51.7% | 199,4 k € |
| Debts | 2,1 M € | -13.6% | 2,5 M € | -25.2% | 3,3 M € | +63.9% | 2 M € | -10.6% | 2,3 M € | -9.1% | 2,5 M € | +69.8% | 1,5 M € | +17.3% | 1,3 M € | -0.5% | 1,3 M € | +29.8% | 970,1 k € | -22.2% | 1,2 M € | +202% | 412,2 k € | +80.7% | 228,2 k € | -20.6% | 287,5 k € | +29.9% | 221,3 k € |
| Other | |||||||||||||||||||||||||||||
| Workforce | 39,8 ETP | -1.7% | 40,5 ETP | -11.6% | 45,8 ETP | +5.8% | 43,3 ETP | +12.2% | 38,6 ETP | +13.9% | 33,9 ETP | +39.5% | 24,3 ETP | +48.2% | 16,4 ETP | +39.0% | 11,8 ETP | +9.3% | 10,8 ETP | +42.1% | 7,6 ETP | +31.0% | 5,8 ETP | +93.3% | 3,0 ETP | +30.4% | 2,3 ETP | +27.8% | 1,8 ETP |
Indicative valuation
As an indication, this company is worth
Board of directors
Seen on filing of 31/12/2025 · 2 active · 6 ended
Other companies at this address
| Company | CBE no. |
|---|---|
Amalus Therapeutics● Bankrupt | 0803.929.268 |
APCOR R&M● Active | 0600.952.909 |
Ardoyen● Active | 0875.102.821 |
AVROXA● Active | 0687.774.936 |
Benebiose● Active | 0784.521.548 |
BioNeering● Active | 0807.194.309 |
CONTREL EUROPE● Active | 0426.204.637 |
CRODEON TECHNOLOGIES● Active | 0642.754.761 |
Cryptobiotix● Active | 0762.565.104 |
Gulliver Biomed● Active | 0692.527.837 |
ImplicitMeasures.com● Bankrupt | 0657.989.701 |
Inbiose● Active | 0534.887.593 |
| 0440.054.752 | |
INNOVATIVE PHARMACEUTICS● Active | 0883.574.582 |
Inspect● Active | 0645.950.417 |
INVIBES ADVERTISING● Active | 0836.533.938 |
KYTOS● Active | 0768.755.286 |
Lares Solutions● Active | 1015.346.906 |
| 0755.350.975 | |
| 0742.910.132 |
Financials
Full financial information
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 02/07/2026 | 08/10/2025 | 25/06/2024 | 27/06/2023 | 28/06/2022 | 25/06/2021 |
| General meeting | 30/06/2026 | 30/06/2025 | 31/05/2024 | 31/05/2023 | 31/05/2022 | 31/05/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Looking for more information about this company?
Try for 7 daysAnnual accounts filings
17 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 30/06/2026 | 02/07/2026 | Dutch | |
| Abridged model | 31/12/2024 | 30/06/2025 | 08/10/2025 | Dutch | |
| Abridged model | 31/12/2023 | 31/05/2024 | 25/06/2024 | Dutch | |
| Abridged model | 31/12/2022 | 31/05/2023 | 27/06/2023 | Dutch | |
| Abridged model | 31/12/2021 | 31/05/2022 | 28/06/2022 | Dutch | |
| Abridged model | 31/12/2020 | 31/05/2021 | 25/06/2021 | Dutch | |
| Abridged model | 31/12/2019 | 01/09/2020 | 24/09/2020 | Dutch | |
| Abridged model | 31/12/2018 | 31/05/2019 | 06/06/2019 | Dutch | |
| Abridged model | 31/12/2017 | 31/05/2018 | 28/06/2018 | Dutch | |
| Abridged model | 31/12/2016 | 31/05/2017 | 22/06/2017 | Dutch | |
| Abridged model | 31/12/2015 | 31/05/2016 | 14/06/2016 | Dutch | |
| Abridged model | 31/12/2014 | 01/06/2015 | 24/06/2015 | Dutch | |
| Abridged model | 31/12/2013 | 31/05/2014 | 05/06/2014 | Dutch | |
| Abridged model | 31/12/2012 | 31/05/2013 | 07/06/2013 | Dutch | |
| Abridged model | 31/12/2011 | 31/05/2012 | 15/06/2012 | Dutch | |
| Abridged model | 31/12/2010 | 31/05/2011 | 10/06/2011 | Dutch | |
| Abridged model | 31/12/2009 | 31/05/2010 | 25/06/2010 | Dutch |
Valuation
Indicative valuation
As an indication, this company is worth
between 2,5 M€ and 5 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Publications
Belgian Official Gazette publications
- Mandates25/09/2025ONTSLAGEN - BENOEMINGEN
- Mandates16/09/2021ONTSLAGEN - BENOEMINGEN
- Mandates13/09/2021STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - WIJZIGING RECHTSVORM - ONTSLAGEN - BENOEMINGEN
- Restructuring13/03/2020RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
- Restructuring29/10/2019MAATSCHAPPELIJKE ZETEL - RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
- Restructuring28/02/2019RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
- Mandates21/03/2018ONTSLAGEN - BENOEMINGEN
- Capital / shares06/01/2014KAPITAAL - AANDELEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
Source: Belgian Official Gazette
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 202532,7 k €↓
- 2024Annual accounts 2024111 k €↑
- 2023Annual accounts 2023-842,7 k €↓
- 2022Annual accounts 202210,6 k €↓
- 2021Annual accounts 20212,2 M €↑
- 2018Annual accounts 20189 k €↓
- 2017Annual accounts 2017256,9 k €↓
- 2016Annual accounts 2016616,8 k €↓
- 2015Annual accounts 2015642,7 k €↑
- 2014Annual accounts 2014594,1 k €↑
- 2013Annual accounts 2013229,7 k €↑
- 2012Annual accounts 2012121,8 k €↓
- 2011Annual accounts 2011180,5 k €↑
- 2010Annual accounts 2010142,6 k €↓
- 2009Annual accounts 2009165,3 k €
- 24/09/2008IncorporationPrivate limited company